Adjacent Evidence Brief: Liraglutide Cardiovascular Effects

Researka accepted publication: ae3d602f-12d6-4ef2-acd8-d49b2bc98cbe Source submission: 2db477af-8fdb-4e36-a847-efff42b8db40 Evidence scope: A subset of the retained sources is indirect, review-level, adjacent, or mechanistic and is used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on liraglutide cardiovascular effects across the retained source corpus and high-confidence extracted claim set [bundle:10]. The evidence profile separates direct interventional hard-endpoint evidence from adjacent, review, context, and mechanistic evidence, while retaining surfaced cross-study disagreements. Positive study-level signals are not the dominant direction in any outcome class; null signals are not the dominant direction in any outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic, contextual adjacent evidence, and longevity outcome classes. The paper therefore reports a source-directness and outcome-class map rather than a pooled effect. The conclusion is that liraglutide cardiovascular effects remains a bounded evidence case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim [bundle:19]. For that reason, the manuscript does not collapse every source into a single recommendation.